Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2004 2
2005 2
2006 1
2007 1
2008 1
2009 4
2010 4
2011 2
2012 2
2013 4
2014 3
2015 4
2016 5
2017 4
2018 4
2019 5
2020 4
2021 3
2022 7
2023 9
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

68 results

Results by year

Filters applied: . Clear all
Page 1
[Rhabdomyolysis].
Shirota H, Ohishi T. Shirota H, et al. Nihon Rinsho. 2015 Feb;73 Suppl 2:499-502. Nihon Rinsho. 2015. PMID: 25831811 Japanese. No abstract available.
CpG Oligonucleotides as Cancer Vaccine Adjuvants.
Shirota H, Tross D, Klinman DM. Shirota H, et al. Vaccines (Basel). 2015 May 8;3(2):390-407. doi: 10.3390/vaccines3020390. Vaccines (Basel). 2015. PMID: 26343193 Free PMC article. Review.
Dabrafenib and trametinib administration in patients with BRAF V600E/R or non-V600 BRAF mutated advanced solid tumours (BELIEVE, NCCH1901): a multicentre, open-label, and single-arm phase II trial.
Shimoi T, Sunami K, Tahara M, Nishiwaki S, Tanaka S, Baba E, Kanai M, Kinoshita I, Shirota H, Hayashi H, Nishida N, Kubo T, Mamesaya N, Ando Y, Okita N, Shibata T, Nakamura K, Yamamoto N. Shimoi T, et al. Among authors: shirota h. EClinicalMedicine. 2024 Feb 2;69:102447. doi: 10.1016/j.eclinm.2024.102447. eCollection 2024 Mar. EClinicalMedicine. 2024. PMID: 38333370 Free PMC article.
Synthetic oligonucleotides as modulators of inflammation.
Klinman D, Shirota H, Tross D, Sato T, Klaschik S. Klinman D, et al. Among authors: shirota h. J Leukoc Biol. 2008 Oct;84(4):958-64. doi: 10.1189/jlb.1107775. Epub 2008 Apr 22. J Leukoc Biol. 2008. PMID: 18430787 Free PMC article. Review.
Concordance Between Recommendations From Multidisciplinary Molecular Tumor Boards and Central Consensus for Cancer Treatment in Japan.
Naito Y, Sunami K, Kage H, Komine K, Amano T, Imai M, Koyama T, Ennishi D, Kanai M, Kenmotsu H, Maeda T, Morita S, Sakai D, Watanabe K, Shirota H, Kinoshita I, Yoshioka M, Mamesaya N, Ito M, Kohsaka S, Saigusa Y, Yamamoto K, Hirata M, Tsuchihara K, Yoshino T. Naito Y, et al. Among authors: shirota h. JAMA Netw Open. 2022 Dec 1;5(12):e2245081. doi: 10.1001/jamanetworkopen.2022.45081. JAMA Netw Open. 2022. PMID: 36469316 Free PMC article.
Human resources for administrative work to carry out a comprehensive genomic profiling test in Japan.
Kage H, Oda K, Muto M, Tsuchihara K, Okita N, Okuma Y, Kikuchi J, Shirota H, Hayashi H, Kokuryo T, Sakai D, Hirasawa A, Kubo M, Kenmotsu H, Akiyama N, Shinozaki-Ushiku A, Tanabe M, Ushiku T, Miyagawa K, Seto Y. Kage H, et al. Among authors: shirota h. Cancer Sci. 2023 Jul;114(7):3041-3049. doi: 10.1111/cas.15833. Epub 2023 May 10. Cancer Sci. 2023. PMID: 37165760 Free PMC article.
Clinical decisions by the molecular tumor board on comprehensive genomic profiling tests in Japan: A retrospective observational study.
Shirota H, Komine K, Takahashi M, Takahashi S, Miyauchi E, Niizuma H, Tada H, Shimada M, Niihori T, Aoki Y, Sugiyama I, Kawamura M, Yasuda J, Suzuki S, Iwaya T, Saito M, Saito T, Shibata H, Furukawa T, Ishioka C. Shirota H, et al. Cancer Med. 2023 Mar;12(5):6170-6181. doi: 10.1002/cam4.5349. Epub 2022 Oct 17. Cancer Med. 2023. PMID: 36251535 Free PMC article.
68 results